https://orcid.org/0000-0002-7174-4651
References
- Cines DB, Liebman HA. The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation. Hematol Oncol Clin North Am. 2009;23:1155–1161. doi: 10.1016/j.hoc.2009.09.003
- Neunert C, Lim W, Crowther M, et al. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–4207. doi: 10.1182/blood-2010-08-302984
- Diz-Küçükkaya R, Hacihanefioğlu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98:1760–1764. doi: 10.1182/blood.V98.6.1760
- Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol. 2008;142:638–643. doi: 10.1111/j.1365-2141.2008.07228.x
- Uthman I, Godeau B, Taher A, et al. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev. 2008;22:187–194. doi: 10.1016/j.blre.2008.03.005
- Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84:4203–4208.
- Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2009;7:1737–1740. doi: 10.1111/j.1538-7836.2009.03555.x
- Ruggeri M, Tosetto A, Palandri F, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014;12:1266–1273. doi: 10.1111/jth.12636
- Rodeghiero F. Is ITP a thrombophilic disorder? Am J Hematol. 2016;91:39–45. doi: 10.1002/ajh.24234
- Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113:6511–6521. doi: 10.1182/blood-2009-01-129155
- Fabris F, Steffan A, Cordiano I, et al. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol. 1994;53:232–236. doi: 10.1111/j.1600-0609.1994.tb00195.x
- Macchi L, Rispal P, Clofent-Sanchez G, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol. 1997;98:336–341. doi: 10.1046/j.1365-2141.1997.2243038.x
- Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome. Br J Haematol. 1996;93:1–5. doi: 10.1046/j.1365-2141.1996.390969.x
- Kumar D, Roubey RA. Use of rituximab in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12:40–44. doi: 10.1007/s11926-009-0074-5
- Shi T, Giannakopoulos B, Yan X, et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum. 2006;54:2558–2567. doi: 10.1002/art.21968